NCT02908347 - Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

February 28, 2017

Conditions

PsoriasisPlaque Psoriasis

Interventions

DRUG

MP1032

hard gelatine capsules containing 50 mg MP1032 as active ingredient

DRUG

Placebo

hard gelatine capsules without active ingredient

Trial Locations (4)

Rothaar Studien GmbH, Berlin

PAREXEL International GmbH, Klinikum Westend, Berlin

Gemeinschaftspraxis Prof. Dr. Vanscheidt und Dr. Ukat, Freiburg im Breisgau

Klinische Forschung Dresden GmbH, Dresden